Literature DB >> 35284505

Hepatocellular carcinoma with complete response to the immunotherapy: the oncologist's dilemma.

Mansour Al-Moundhri1, Antonio Cubisino2, Fabrizio Panaro2,3,4.   

Abstract

Entities:  

Year:  2022        PMID： 35284505      PMCID： PMC8847859          DOI： 10.21037/hbsn-21-499

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  11 in total

Review 1.  Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction.

Authors:  Fasiha Kanwal; Amit G Singal
Journal:  Gastroenterology       Date:  2019-04-12       Impact factor: 22.682

Review 2.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Authors:  Filipe Martins; Latifyan Sofiya; Gerasimos P Sykiotis; Faiza Lamine; Michel Maillard; Montserrat Fraga; Keyvan Shabafrouz; Camillo Ribi; Anne Cairoli; Yan Guex-Crosier; Thierry Kuntzer; Olivier Michielin; Solange Peters; Georges Coukos; Francois Spertini; John A Thompson; Michel Obeid
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 3.  Goals and targets for personalized therapy for HCC.

Authors:  Thomas Couri; Anjana Pillai
Journal:  Hepatol Int       Date:  2019-01-01       Impact factor: 6.047

4.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

5.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Authors:  I Puzanov; A Diab; K Abdallah; C O Bingham; C Brogdon; R Dadu; L Hamad; S Kim; M E Lacouture; N R LeBoeuf; D Lenihan; C Onofrei; V Shannon; R Sharma; A W Silk; D Skondra; M E Suarez-Almazor; Y Wang; K Wiley; H L Kaufman; M S Ernstoff
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

6.  Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.

Authors:  Xin Zhang; Jingjing Wang; Juanjuan Shi; Xiaoli Jia; Shuangsuo Dang; Wenjun Wang
Journal:  JAMA Netw Open       Date:  2021-04-01

7.  Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Vogel; A Cervantes; I Chau; B Daniele; J M Llovet; T Meyer; J-C Nault; U Neumann; J Ricke; B Sangro; P Schirmacher; C Verslype; C J Zech; D Arnold; E Martinelli
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

Review 8.  Challenges of advanced hepatocellular carcinoma.

Authors:  Stefano Colagrande; Andrea L Inghilesi; Sami Aburas; Gian G Taliani; Cosimo Nardi; Fabio Marra
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

Review 9.  PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.

Authors:  Marcus Unterrainer; Michael Ruzicka; Matthias P Fabritius; Lena M Mittlmeier; Michael Winkelmann; Johannes Rübenthaler; Matthias Brendel; Marion Subklewe; Michael von Bergwelt-Baildon; Jens Ricke; Wolfgang G Kunz; Clemens C Cyran
Journal:  Eur Radiol Exp       Date:  2020-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.